GFP Adeno-Associated Virus ( AAV-RGDLGLS )

Adeno-associated virus (AAV) vectors hold promise as safe and effective tools for gene therapy. Their desirable safety profile has been demonstrated in multiple clinical trials. Vector administration does not induce a strong cellular immune response and the risk of accidental integration into the human genome is low. Research efforts targeting the clinical application of AAV vectors have focused on improving targeting specificity and transduction efficiency on the one hand and evaluating suitable therapeutic transgenes on the other. The strategies in the former area range widely. It includes exploiting the natural diversity of AAV serotypes, inserting targeting peptides, using bispecific conjugates, and inserting random peptide libraries exposed on the capsid surface, allowing for the identification of suitable capsid variants by biopanning. GFP AAV-RGDLGLS is derived from AAV serotype 2 (AAV2), a serotype commonly used in gene therapy due to its safety profile and effectiveness in transducing a variety of cell types. A key modification of the virus is the insertion of the peptide sequence RGDLGLS at position I588 of the AAV2 capsid protein. This strategic insertion exploits the properties of the RGDLGLS peptide and may enhance the affinity and specificity of the virus for tumor cells. The presence of the RGD peptide sequence is particularly important because it is known to interact with integrins that are often overexpressed on the surface of tumor cells, thereby facilitating targeted binding and entry into these cells.